INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24701, 31792, 'Baricitinib', 'Neoplasms', 'Malignancies (including lymphomas and solid tumors) have been reported in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions; lymphomas and other malignancies have been seen in patients treated with baricitinib or upadacitinib.  Patients who are current or past smokers are at additional increased risk of malignancies.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, pacritinib, and fedratinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with a known malignancy (other than successfully treated nonmelanoma skin cancer), patients who develop a malignancy during therapy, and patients who are current or past smokers.  Periodic skin examination is recommended for patients who are at increased risk for skin cancer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24702, 281, 'Baricitinib', 'Thrombosis', 'Thrombosis (including deep venous thrombosis, pulmonary embolism, and arterial thrombosis) has occurred in patients treated for inflammatory conditions with Janus kinase (JAK) inhibitors, including baricitinib, tofacitinib, and upadacitinib; many of these adverse events were serious and some resulted in death.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, fedratinib, and pacritinib.  Baricitinib, pacritinib, tofacitinib, and upadacitinib should be avoided in patients who may be at increased risk of thrombosis; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response.  If symptoms of thrombosis occur, baricitinib, pacritinib, tofacitinib, and upadacitinib should be discontinued and patients should be evaluated promptly and treated appropriately.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24703, 24035, 'Baricitinib', 'Thrombosis', 'Thrombosis (including deep venous thrombosis, pulmonary embolism, and arterial thrombosis) has occurred in patients treated for inflammatory conditions with Janus kinase (JAK) inhibitors, including baricitinib, tofacitinib, and upadacitinib; many of these adverse events were serious and some resulted in death.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, fedratinib, and pacritinib.  Baricitinib, pacritinib, tofacitinib, and upadacitinib should be avoided in patients who may be at increased risk of thrombosis; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response.  If symptoms of thrombosis occur, baricitinib, pacritinib, tofacitinib, and upadacitinib should be discontinued and patients should be evaluated promptly and treated appropriately.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24704, 24036, 'Baricitinib', 'Thrombosis', 'Thrombosis (including deep venous thrombosis, pulmonary embolism, and arterial thrombosis) has occurred in patients treated for inflammatory conditions with Janus kinase (JAK) inhibitors, including baricitinib, tofacitinib, and upadacitinib; many of these adverse events were serious and some resulted in death.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, fedratinib, and pacritinib.  Baricitinib, pacritinib, tofacitinib, and upadacitinib should be avoided in patients who may be at increased risk of thrombosis; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response.  If symptoms of thrombosis occur, baricitinib, pacritinib, tofacitinib, and upadacitinib should be discontinued and patients should be evaluated promptly and treated appropriately.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24705, 31767, 'Baricitinib', 'Thrombosis', 'Thrombosis (including deep venous thrombosis, pulmonary embolism, and arterial thrombosis) has occurred in patients treated for inflammatory conditions with Janus kinase (JAK) inhibitors, including baricitinib, tofacitinib, and upadacitinib; many of these adverse events were serious and some resulted in death.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, fedratinib, and pacritinib.  Baricitinib, pacritinib, tofacitinib, and upadacitinib should be avoided in patients who may be at increased risk of thrombosis; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response.  If symptoms of thrombosis occur, baricitinib, pacritinib, tofacitinib, and upadacitinib should be discontinued and patients should be evaluated promptly and treated appropriately.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24706, 31792, 'Baricitinib', 'Thrombosis', 'Thrombosis (including deep venous thrombosis, pulmonary embolism, and arterial thrombosis) has occurred in patients treated for inflammatory conditions with Janus kinase (JAK) inhibitors, including baricitinib, tofacitinib, and upadacitinib; many of these adverse events were serious and some resulted in death.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, fedratinib, and pacritinib.  Baricitinib, pacritinib, tofacitinib, and upadacitinib should be avoided in patients who may be at increased risk of thrombosis; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response.  If symptoms of thrombosis occur, baricitinib, pacritinib, tofacitinib, and upadacitinib should be discontinued and patients should be evaluated promptly and treated appropriately.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24707, 281, 'Baricitinib', 'Diabetes Mellitus', 'The use of baricitinib increases the risk of infections in diabetic patients.  Caution is recommended when treating patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24708, 24035, 'Baricitinib', 'Diabetes Mellitus', 'The use of baricitinib increases the risk of infections in diabetic patients.  Caution is recommended when treating patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24709, 24036, 'Baricitinib', 'Diabetes Mellitus', 'The use of baricitinib increases the risk of infections in diabetic patients.  Caution is recommended when treating patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24710, 31767, 'Baricitinib', 'Diabetes Mellitus', 'The use of baricitinib increases the risk of infections in diabetic patients.  Caution is recommended when treating patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24711, 31792, 'Baricitinib', 'Diabetes Mellitus', 'The use of baricitinib increases the risk of infections in diabetic patients.  Caution is recommended when treating patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24712, 281, 'Baricitinib', 'Peptic Ulcer Perforation', 'Baricitinib may cause gastrointestinal perforation.  Baricitinib-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with history of diverticulitis) should be monitored.  Patients presenting with new onset abdominal symptoms should be evaluated promptly for early identification of gastrointestinal perforation.  Caution is recommended for patients who may be at increased risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24713, 24035, 'Baricitinib', 'Peptic Ulcer Perforation', 'Baricitinib may cause gastrointestinal perforation.  Baricitinib-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with history of diverticulitis) should be monitored.  Patients presenting with new onset abdominal symptoms should be evaluated promptly for early identification of gastrointestinal perforation.  Caution is recommended for patients who may be at increased risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24714, 24036, 'Baricitinib', 'Peptic Ulcer Perforation', 'Baricitinib may cause gastrointestinal perforation.  Baricitinib-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with history of diverticulitis) should be monitored.  Patients presenting with new onset abdominal symptoms should be evaluated promptly for early identification of gastrointestinal perforation.  Caution is recommended for patients who may be at increased risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24715, 31767, 'Baricitinib', 'Peptic Ulcer Perforation', 'Baricitinib may cause gastrointestinal perforation.  Baricitinib-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with history of diverticulitis) should be monitored.  Patients presenting with new onset abdominal symptoms should be evaluated promptly for early identification of gastrointestinal perforation.  Caution is recommended for patients who may be at increased risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24716, 31792, 'Baricitinib', 'Peptic Ulcer Perforation', 'Baricitinib may cause gastrointestinal perforation.  Baricitinib-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with history of diverticulitis) should be monitored.  Patients presenting with new onset abdominal symptoms should be evaluated promptly for early identification of gastrointestinal perforation.  Caution is recommended for patients who may be at increased risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24717, 281, 'Baricitinib', 'Hepatic Insufficiency', 'Baricitinib is not recommended in patients with rheumatoid arthritis or alopecia areata with severe liver dysfunction; baricitinib should only be used in patients with coronavirus disease 2019 (COVID-19) and severe liver dysfunction if the potential benefit outweighs the potential risk.  No dose adjustment is necessary in patients with mild or moderate liver dysfunction.  Treatment with baricitinib was associated with increased incidence of liver enzyme elevation compared to placebo.  Liver enzymes should be evaluated at baseline and thereafter according to routine patient management; prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury.  If increases in ALT or AST are observed and drug-induced liver injury is suspected, baricitinib should be interrupted until this diagnosis is excluded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24718, 24035, 'Baricitinib', 'Hepatic Insufficiency', 'Baricitinib is not recommended in patients with rheumatoid arthritis or alopecia areata with severe liver dysfunction; baricitinib should only be used in patients with coronavirus disease 2019 (COVID-19) and severe liver dysfunction if the potential benefit outweighs the potential risk.  No dose adjustment is necessary in patients with mild or moderate liver dysfunction.  Treatment with baricitinib was associated with increased incidence of liver enzyme elevation compared to placebo.  Liver enzymes should be evaluated at baseline and thereafter according to routine patient management; prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury.  If increases in ALT or AST are observed and drug-induced liver injury is suspected, baricitinib should be interrupted until this diagnosis is excluded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24719, 24036, 'Baricitinib', 'Hepatic Insufficiency', 'Baricitinib is not recommended in patients with rheumatoid arthritis or alopecia areata with severe liver dysfunction; baricitinib should only be used in patients with coronavirus disease 2019 (COVID-19) and severe liver dysfunction if the potential benefit outweighs the potential risk.  No dose adjustment is necessary in patients with mild or moderate liver dysfunction.  Treatment with baricitinib was associated with increased incidence of liver enzyme elevation compared to placebo.  Liver enzymes should be evaluated at baseline and thereafter according to routine patient management; prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury.  If increases in ALT or AST are observed and drug-induced liver injury is suspected, baricitinib should be interrupted until this diagnosis is excluded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24720, 31767, 'Baricitinib', 'Hepatic Insufficiency', 'Baricitinib is not recommended in patients with rheumatoid arthritis or alopecia areata with severe liver dysfunction; baricitinib should only be used in patients with coronavirus disease 2019 (COVID-19) and severe liver dysfunction if the potential benefit outweighs the potential risk.  No dose adjustment is necessary in patients with mild or moderate liver dysfunction.  Treatment with baricitinib was associated with increased incidence of liver enzyme elevation compared to placebo.  Liver enzymes should be evaluated at baseline and thereafter according to routine patient management; prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury.  If increases in ALT or AST are observed and drug-induced liver injury is suspected, baricitinib should be interrupted until this diagnosis is excluded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24721, 31792, 'Baricitinib', 'Hepatic Insufficiency', 'Baricitinib is not recommended in patients with rheumatoid arthritis or alopecia areata with severe liver dysfunction; baricitinib should only be used in patients with coronavirus disease 2019 (COVID-19) and severe liver dysfunction if the potential benefit outweighs the potential risk.  No dose adjustment is necessary in patients with mild or moderate liver dysfunction.  Treatment with baricitinib was associated with increased incidence of liver enzyme elevation compared to placebo.  Liver enzymes should be evaluated at baseline and thereafter according to routine patient management; prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury.  If increases in ALT or AST are observed and drug-induced liver injury is suspected, baricitinib should be interrupted until this diagnosis is excluded.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24722, 281, 'Baricitinib', 'Hyperlipidemias', 'In controlled clinical trials in patients with rheumatoid arthritis, baricitinib treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.  Lipid parameters should be assessed at baseline and about 12 weeks after initiation of therapy in patients with rheumatoid arthritis or alopecia areata.  Patients should be managed according to clinical guidelines for the management of hyperlipidemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24723, 24035, 'Baricitinib', 'Hyperlipidemias', 'In controlled clinical trials in patients with rheumatoid arthritis, baricitinib treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.  Lipid parameters should be assessed at baseline and about 12 weeks after initiation of therapy in patients with rheumatoid arthritis or alopecia areata.  Patients should be managed according to clinical guidelines for the management of hyperlipidemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24724, 24036, 'Baricitinib', 'Hyperlipidemias', 'In controlled clinical trials in patients with rheumatoid arthritis, baricitinib treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.  Lipid parameters should be assessed at baseline and about 12 weeks after initiation of therapy in patients with rheumatoid arthritis or alopecia areata.  Patients should be managed according to clinical guidelines for the management of hyperlipidemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24725, 31767, 'Baricitinib', 'Hyperlipidemias', 'In controlled clinical trials in patients with rheumatoid arthritis, baricitinib treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.  Lipid parameters should be assessed at baseline and about 12 weeks after initiation of therapy in patients with rheumatoid arthritis or alopecia areata.  Patients should be managed according to clinical guidelines for the management of hyperlipidemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24726, 31792, 'Baricitinib', 'Hyperlipidemias', 'In controlled clinical trials in patients with rheumatoid arthritis, baricitinib treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.  Lipid parameters should be assessed at baseline and about 12 weeks after initiation of therapy in patients with rheumatoid arthritis or alopecia areata.  Patients should be managed according to clinical guidelines for the management of hyperlipidemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24727, 281, 'Baricitinib', 'Hematologic Diseases', 'Treatment with baricitinib was associated with an increased incidence of neutropenia, lymphopenia, and anemia compared to placebo.  Therapy should not be started or should be interrupted in patients with rheumatoid arthritis or alopecia areata with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1000 cells/mm3, or hemoglobin level less than 8 g/dL; therapy should not be started or should be interrupted in patients with coronavirus disease 2019 (COVID-19) with an ALC less than 200 cells/mm3 or ANC less than 500 cells/mm3.  Evaluation at baseline and thereafter according to routine patient management is recommended; dosing should be modified based on ALC, ANC, and/or hemoglobin levels.  Caution is recommended in patients who may be at increased risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24728, 24035, 'Baricitinib', 'Hematologic Diseases', 'Treatment with baricitinib was associated with an increased incidence of neutropenia, lymphopenia, and anemia compared to placebo.  Therapy should not be started or should be interrupted in patients with rheumatoid arthritis or alopecia areata with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1000 cells/mm3, or hemoglobin level less than 8 g/dL; therapy should not be started or should be interrupted in patients with coronavirus disease 2019 (COVID-19) with an ALC less than 200 cells/mm3 or ANC less than 500 cells/mm3.  Evaluation at baseline and thereafter according to routine patient management is recommended; dosing should be modified based on ALC, ANC, and/or hemoglobin levels.  Caution is recommended in patients who may be at increased risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24729, 24036, 'Baricitinib', 'Hematologic Diseases', 'Treatment with baricitinib was associated with an increased incidence of neutropenia, lymphopenia, and anemia compared to placebo.  Therapy should not be started or should be interrupted in patients with rheumatoid arthritis or alopecia areata with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1000 cells/mm3, or hemoglobin level less than 8 g/dL; therapy should not be started or should be interrupted in patients with coronavirus disease 2019 (COVID-19) with an ALC less than 200 cells/mm3 or ANC less than 500 cells/mm3.  Evaluation at baseline and thereafter according to routine patient management is recommended; dosing should be modified based on ALC, ANC, and/or hemoglobin levels.  Caution is recommended in patients who may be at increased risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24730, 31767, 'Baricitinib', 'Hematologic Diseases', 'Treatment with baricitinib was associated with an increased incidence of neutropenia, lymphopenia, and anemia compared to placebo.  Therapy should not be started or should be interrupted in patients with rheumatoid arthritis or alopecia areata with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1000 cells/mm3, or hemoglobin level less than 8 g/dL; therapy should not be started or should be interrupted in patients with coronavirus disease 2019 (COVID-19) with an ALC less than 200 cells/mm3 or ANC less than 500 cells/mm3.  Evaluation at baseline and thereafter according to routine patient management is recommended; dosing should be modified based on ALC, ANC, and/or hemoglobin levels.  Caution is recommended in patients who may be at increased risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24731, 31792, 'Baricitinib', 'Hematologic Diseases', 'Treatment with baricitinib was associated with an increased incidence of neutropenia, lymphopenia, and anemia compared to placebo.  Therapy should not be started or should be interrupted in patients with rheumatoid arthritis or alopecia areata with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1000 cells/mm3, or hemoglobin level less than 8 g/dL; therapy should not be started or should be interrupted in patients with coronavirus disease 2019 (COVID-19) with an ALC less than 200 cells/mm3 or ANC less than 500 cells/mm3.  Evaluation at baseline and thereafter according to routine patient management is recommended; dosing should be modified based on ALC, ANC, and/or hemoglobin levels.  Caution is recommended in patients who may be at increased risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24732, 281, 'Baricitinib', 'Kidney Diseases', 'Renal function significantly affects baricitinib exposure; renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion.  Baricitinib is not recommended in patients with rheumatoid arthritis or alopecia areata and severe renal dysfunction (estimated GFR [eGFR] less than 30 mL/min/1.73 m2); baricitinib is not recommended in patients with coronavirus disease 2019 (COVID-19) who are on dialysis, have ESRD, or have acute kidney injury (eGFR less than 15 mL/min/1.73 m2).  Dosage modifications are recommended for patients with rheumatoid arthritis or alopecia areata with moderate renal dysfunction (eGFR 30 to less than 60 mL/min/1.73 m2) and COVID-19 patients with moderate or severe renal dysfunction (eGFR 15 to less than 60 mL/min/1.73 m2); care should be exercised when using this agent in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24733, 24035, 'Baricitinib', 'Kidney Diseases', 'Renal function significantly affects baricitinib exposure; renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion.  Baricitinib is not recommended in patients with rheumatoid arthritis or alopecia areata and severe renal dysfunction (estimated GFR [eGFR] less than 30 mL/min/1.73 m2); baricitinib is not recommended in patients with coronavirus disease 2019 (COVID-19) who are on dialysis, have ESRD, or have acute kidney injury (eGFR less than 15 mL/min/1.73 m2).  Dosage modifications are recommended for patients with rheumatoid arthritis or alopecia areata with moderate renal dysfunction (eGFR 30 to less than 60 mL/min/1.73 m2) and COVID-19 patients with moderate or severe renal dysfunction (eGFR 15 to less than 60 mL/min/1.73 m2); care should be exercised when using this agent in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24734, 24036, 'Baricitinib', 'Kidney Diseases', 'Renal function significantly affects baricitinib exposure; renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion.  Baricitinib is not recommended in patients with rheumatoid arthritis or alopecia areata and severe renal dysfunction (estimated GFR [eGFR] less than 30 mL/min/1.73 m2); baricitinib is not recommended in patients with coronavirus disease 2019 (COVID-19) who are on dialysis, have ESRD, or have acute kidney injury (eGFR less than 15 mL/min/1.73 m2).  Dosage modifications are recommended for patients with rheumatoid arthritis or alopecia areata with moderate renal dysfunction (eGFR 30 to less than 60 mL/min/1.73 m2) and COVID-19 patients with moderate or severe renal dysfunction (eGFR 15 to less than 60 mL/min/1.73 m2); care should be exercised when using this agent in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24735, 31767, 'Baricitinib', 'Kidney Diseases', 'Renal function significantly affects baricitinib exposure; renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion.  Baricitinib is not recommended in patients with rheumatoid arthritis or alopecia areata and severe renal dysfunction (estimated GFR [eGFR] less than 30 mL/min/1.73 m2); baricitinib is not recommended in patients with coronavirus disease 2019 (COVID-19) who are on dialysis, have ESRD, or have acute kidney injury (eGFR less than 15 mL/min/1.73 m2).  Dosage modifications are recommended for patients with rheumatoid arthritis or alopecia areata with moderate renal dysfunction (eGFR 30 to less than 60 mL/min/1.73 m2) and COVID-19 patients with moderate or severe renal dysfunction (eGFR 15 to less than 60 mL/min/1.73 m2); care should be exercised when using this agent in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24736, 31792, 'Baricitinib', 'Kidney Diseases', 'Renal function significantly affects baricitinib exposure; renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion.  Baricitinib is not recommended in patients with rheumatoid arthritis or alopecia areata and severe renal dysfunction (estimated GFR [eGFR] less than 30 mL/min/1.73 m2); baricitinib is not recommended in patients with coronavirus disease 2019 (COVID-19) who are on dialysis, have ESRD, or have acute kidney injury (eGFR less than 15 mL/min/1.73 m2).  Dosage modifications are recommended for patients with rheumatoid arthritis or alopecia areata with moderate renal dysfunction (eGFR 30 to less than 60 mL/min/1.73 m2) and COVID-19 patients with moderate or severe renal dysfunction (eGFR 15 to less than 60 mL/min/1.73 m2); care should be exercised when using this agent in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24737, 281, 'Baricitinib', 'Hepatitis, Viral, Human', 'Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), was reported in clinical studies with baricitinib.  Patients should be screened for viral hepatitis in accordance with clinical guidelines before starting therapy with baricitinib.  If a patient develops herpes zoster during therapy, treatment with baricitinib should be interrupted until the episode resolves.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24738, 24035, 'Baricitinib', 'Hepatitis, Viral, Human', 'Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), was reported in clinical studies with baricitinib.  Patients should be screened for viral hepatitis in accordance with clinical guidelines before starting therapy with baricitinib.  If a patient develops herpes zoster during therapy, treatment with baricitinib should be interrupted until the episode resolves.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24739, 24036, 'Baricitinib', 'Hepatitis, Viral, Human', 'Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), was reported in clinical studies with baricitinib.  Patients should be screened for viral hepatitis in accordance with clinical guidelines before starting therapy with baricitinib.  If a patient develops herpes zoster during therapy, treatment with baricitinib should be interrupted until the episode resolves.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24740, 31767, 'Baricitinib', 'Hepatitis, Viral, Human', 'Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), was reported in clinical studies with baricitinib.  Patients should be screened for viral hepatitis in accordance with clinical guidelines before starting therapy with baricitinib.  If a patient develops herpes zoster during therapy, treatment with baricitinib should be interrupted until the episode resolves.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24741, 31792, 'Baricitinib', 'Hepatitis, Viral, Human', 'Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), was reported in clinical studies with baricitinib.  Patients should be screened for viral hepatitis in accordance with clinical guidelines before starting therapy with baricitinib.  If a patient develops herpes zoster during therapy, treatment with baricitinib should be interrupted until the episode resolves.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24742, 13289, 'Selenium', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24743, 13642, 'Selenium', 'Kidney Diseases', 'The trace metals, chromium and zinc, are excreted primarily in the urine.  Selenium is partially excreted in the urine.  Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24744, 13289, 'Selenium', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24745, 13642, 'Selenium', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24746, 0, 'Secobarbital', 'Alcoholic Intoxication', 'The use of barbiturates is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of barbiturates may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with barbiturates should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24747, 0, 'Secobarbital', 'Substance-Related Disorders', 'Barbiturates have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages.  Abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance to a barbiturate, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with barbiturates.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of barbiturates should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24748, 0, 'Secobarbital', 'Liver Diseases', 'Barbiturates are extensively metabolized by the liver.  The plasma clearance of barbiturates may be decreased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with barbiturates should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Barbiturates are not recommended for use in patients with cirrhosis, hepatic failure, hepatic coma, or other severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24749, 0, 'Secobarbital', 'Porphyrias', 'The use of barbiturates is contraindicated in patients with a history of porphyria.  Barbiturates may exacerbate acute intermittent porphyria or porphyria variegata by inducing the enzymes responsible for porphyrin synthesis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24750, 0, 'Secobarbital', 'Exanthema', 'Skin eruptions may precede rare but potentially fatal barbiturate-induced reactions such as systemic lupus erythematosus and exfoliative dermatitis, the latter of which may be accompanied by hepatitis and jaundice.  Therapy with barbiturates should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to barbiturates.  Barbiturate therapy should be withdrawn promptly at the first sign of a dermatologic adverse effect.  However, cutaneous reactions may proceed to an irreversible stage even after cessation of medication due to the slow rate of metabolism and excretion of barbiturates.  Patients should be advised to promptly report signs that may indicate impending development of barbiturate-related cutaneous lesions, including high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Rashes may be more likely to occur with phenobarbital and mephobarbital.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24751, 0, 'Secobarbital', 'Respiratory Insufficiency', 'Barbiturates may produce severe respiratory depression, apnea, laryngospasm, bronchospasm and cough, particularly during rapid intravenous administration.  In usual hypnotic dosages, the degree of respiratory depression produced is similar to that which occurs during physiologic sleep, while at higher dosages, the rate, depth and volume of respiration may be markedly decreased.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with barbiturates should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Barbiturates, especially injectable formulations, should generally be avoided in patients with sleep apnea, hypoxia, or severe pulmonary diseases in which dyspnea or obstruction is evident.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24752, 0, 'Secobarbital', 'Cardiovascular Diseases', 'The intravenous administration of barbiturates may produce severe cardiovascular reactions such as bradycardia, hypertension, or vasodilation with fall in blood pressure, particularly during rapid infusion.  Parenteral therapy with barbiturates should be administered cautiously in patients with hypertension, hypotension, or cardiac disease.  The intravenous administration of barbiturates should be reserved for emergency treatment of acute seizures or for anesthesia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24753, 0, 'Secobarbital', 'Hypotension', 'Barbiturates should not be administered by injection to patients in shock or coma or who have recently received another respiratory depressant.  The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24754, 0, 'Secobarbital', 'Adrenal Insufficiency', 'Barbiturates, especially phenobarbital, secobarbital and butabarbital, may diminish the systemic effects of exogenous and endogenous corticosteroids via induction of hepatic microsomal enzymes, thereby accelerating the metabolism of corticosteroids.  In addition, barbiturates may interfere with pituitary corticotropin production.  Therapy with barbiturates should be administered cautiously in patients with adrenal insufficiency.  Patients with borderline hypoadrenalism should be monitored closely, and patients receiving steroid supplementation may require an adjustment in dosage when barbiturates are added to or withdrawn from their medication regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24755, 0, 'Secobarbital', 'Depressive Disorder', 'Barbiturates depress the central nervous system and may cause or exacerbate mental depression.  Therapy with barbiturates should be administered cautiously in patients with a history of depression or suicidal tendencies.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24756, 0, 'Secobarbital', 'Hematologic Diseases', 'Hematologic toxicity, including agranulocytosis, thrombocytopenic purpura and megaloblastic anemia, has been reported rarely during use of barbiturates.  Therapy with barbiturates should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Blood counts are recommended prior to and periodically during long-term therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, easy bruising, petechiae, bleeding, pallor, dizziness, or jaundice.  Barbiturate therapy should be discontinued if blood dyscrasias occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24757, 0, 'Secobarbital', 'Osteomalacia', 'Rickets and osteomalacia have rarely been reported following prolonged use of barbiturates, possibly due to increased metabolism of vitamin D as a result of enzyme induction by barbiturates.  Long-term therapy with barbiturates should be administered cautiously in patients with vitamin D deficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24758, 0, 'Secobarbital', 'Psychotic Disorders', 'Paradoxical reactions characterized by excitability and restlessness may occur in pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with barbiturates.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24759, 16835, 'Secukinumab', 'Infections', 'There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors.  Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated.  Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24760, 16836, 'Secukinumab', 'Infections', 'There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors.  Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated.  Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24761, 16835, 'Secukinumab', 'Tuberculosis', 'Before initiating certain interleukin inhibitors, patients should be screened for latent tuberculosis infection with a tuberculin skin test.  Do not administer these agents to patients with an active tuberculosis infection.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy.  Anti-tuberculosis therapy should be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24762, 16836, 'Secukinumab', 'Tuberculosis', 'Before initiating certain interleukin inhibitors, patients should be screened for latent tuberculosis infection with a tuberculin skin test.  Do not administer these agents to patients with an active tuberculosis infection.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy.  Anti-tuberculosis therapy should be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24763, 16835, 'Secukinumab', 'Inflammatory Bowel Diseases', 'New onset and exacerbations of inflammatory bowel disease, in some cases serious, have been reported in patients treated with secukinumab.  Caution should be used when prescribing secukinumab to patients with inflammatory bowel disease.  Patients who are treated with secukinumab should be monitored for signs and symptoms of inflammatory bowel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24764, 16836, 'Secukinumab', 'Inflammatory Bowel Diseases', 'New onset and exacerbations of inflammatory bowel disease, in some cases serious, have been reported in patients treated with secukinumab.  Caution should be used when prescribing secukinumab to patients with inflammatory bowel disease.  Patients who are treated with secukinumab should be monitored for signs and symptoms of inflammatory bowel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24765, 0, 'Sermorelin', 'Hypothyroidism', 'Untreated hypothyroidism can jeopardize the response to sermorelin.  Therefore, thyroid levels should be evaluated prior to initiation of and throughout sermorelin therapy to ensure adequate levels.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24766, 22831, 'Sevoflurane', 'Hyperthermia', 'The use of sevoflurane is contraindicated in patients with known or suspected susceptibility to malignant hyperthermia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24767, 26886, 'Sevoflurane', 'Hyperthermia', 'The use of sevoflurane is contraindicated in patients with known or suspected susceptibility to malignant hyperthermia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24768, 26887, 'Sevoflurane', 'Hyperthermia', 'The use of sevoflurane is contraindicated in patients with known or suspected susceptibility to malignant hyperthermia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24769, 22831, 'Sevoflurane', 'Liver Diseases', 'In a multicenter study to compare the safety of sevoflurane and isoflurane in patients with mild to moderate hepatic impairment, sevoflurane patients had prolonged terminal disposition of fluoride, as evidenced by longer inorganic fluoride half-life than patients with normal hepatic function.  Results of evaluations of laboratory parameters (e.g., ALT, AST, alkaline phosphatase, and total bilirubin, etc.), as well as investigator-reported incidence of adverse events relating to liver function, demonstrate that sevoflurane can be administered to patients with normal or mild-to-moderately impaired hepatic function.  The use of this agent in patients with severe hepatic dysfunction has not been investigated.  Clinical judgment should be exercised when sevoflurane is used in patients with underlying hepatic conditions or under treatment with drugs known to cause hepatic dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24770, 26886, 'Sevoflurane', 'Liver Diseases', 'In a multicenter study to compare the safety of sevoflurane and isoflurane in patients with mild to moderate hepatic impairment, sevoflurane patients had prolonged terminal disposition of fluoride, as evidenced by longer inorganic fluoride half-life than patients with normal hepatic function.  Results of evaluations of laboratory parameters (e.g., ALT, AST, alkaline phosphatase, and total bilirubin, etc.), as well as investigator-reported incidence of adverse events relating to liver function, demonstrate that sevoflurane can be administered to patients with normal or mild-to-moderately impaired hepatic function.  The use of this agent in patients with severe hepatic dysfunction has not been investigated.  Clinical judgment should be exercised when sevoflurane is used in patients with underlying hepatic conditions or under treatment with drugs known to cause hepatic dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24771, 26887, 'Sevoflurane', 'Liver Diseases', 'In a multicenter study to compare the safety of sevoflurane and isoflurane in patients with mild to moderate hepatic impairment, sevoflurane patients had prolonged terminal disposition of fluoride, as evidenced by longer inorganic fluoride half-life than patients with normal hepatic function.  Results of evaluations of laboratory parameters (e.g., ALT, AST, alkaline phosphatase, and total bilirubin, etc.), as well as investigator-reported incidence of adverse events relating to liver function, demonstrate that sevoflurane can be administered to patients with normal or mild-to-moderately impaired hepatic function.  The use of this agent in patients with severe hepatic dysfunction has not been investigated.  Clinical judgment should be exercised when sevoflurane is used in patients with underlying hepatic conditions or under treatment with drugs known to cause hepatic dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24772, 22831, 'Sevoflurane', 'Hyperkalemia', 'The use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period.  Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable.  Early and aggressive intervention to treat the hyperkalemia and resistant arrhythmias is recommended; as is subsequent evaluation for latent neuromuscular disease.  Caution and close monitoring is recommended when using this agent in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24773, 26886, 'Sevoflurane', 'Hyperkalemia', 'The use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period.  Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable.  Early and aggressive intervention to treat the hyperkalemia and resistant arrhythmias is recommended; as is subsequent evaluation for latent neuromuscular disease.  Caution and close monitoring is recommended when using this agent in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24774, 26887, 'Sevoflurane', 'Hyperkalemia', 'The use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period.  Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable.  Early and aggressive intervention to treat the hyperkalemia and resistant arrhythmias is recommended; as is subsequent evaluation for latent neuromuscular disease.  Caution and close monitoring is recommended when using this agent in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24775, 22831, 'Sevoflurane', 'Intracranial Hypertension', 'Studies comparing sevoflurane to isoflurane for maintenance of anesthesia during neurosurgical procedures found no difference between sevoflurane and isoflurane with regard to recovery from anesthesia.  In patients at risk for elevations of intracranial pressure (ICP), sevoflurane should be administered cautiously in conjunction with ICP-reducing maneuvers such as hyperventilation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24776, 26886, 'Sevoflurane', 'Intracranial Hypertension', 'Studies comparing sevoflurane to isoflurane for maintenance of anesthesia during neurosurgical procedures found no difference between sevoflurane and isoflurane with regard to recovery from anesthesia.  In patients at risk for elevations of intracranial pressure (ICP), sevoflurane should be administered cautiously in conjunction with ICP-reducing maneuvers such as hyperventilation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24777, 26887, 'Sevoflurane', 'Intracranial Hypertension', 'Studies comparing sevoflurane to isoflurane for maintenance of anesthesia during neurosurgical procedures found no difference between sevoflurane and isoflurane with regard to recovery from anesthesia.  In patients at risk for elevations of intracranial pressure (ICP), sevoflurane should be administered cautiously in conjunction with ICP-reducing maneuvers such as hyperventilation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24778, 22831, 'Sevoflurane', 'Kidney Diseases', 'Limited data are available on the use of oral sevoflurane in patients with renal insufficiency.  Sevoflurane may be associated with glycosuria and proteinuria when used for long procedures at low flow rates.  Caution is advised when using sevoflurane in these patients as the safety has not been fully established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24779, 26886, 'Sevoflurane', 'Kidney Diseases', 'Limited data are available on the use of oral sevoflurane in patients with renal insufficiency.  Sevoflurane may be associated with glycosuria and proteinuria when used for long procedures at low flow rates.  Caution is advised when using sevoflurane in these patients as the safety has not been fully established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24780, 26887, 'Sevoflurane', 'Kidney Diseases', 'Limited data are available on the use of oral sevoflurane in patients with renal insufficiency.  Sevoflurane may be associated with glycosuria and proteinuria when used for long procedures at low flow rates.  Caution is advised when using sevoflurane in these patients as the safety has not been fully established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24781, 22831, 'Sevoflurane', 'Seizures', 'The use of sevoflurane has been associated with seizures.  The majority of cases were in children and young adults, most of whom had no medical history of seizures.  Seizures have occurred during, or soon after sevoflurane induction, during emergence, and during post-operative recovery up to a day following anesthesia.  Caution and clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24782, 26886, 'Sevoflurane', 'Seizures', 'The use of sevoflurane has been associated with seizures.  The majority of cases were in children and young adults, most of whom had no medical history of seizures.  Seizures have occurred during, or soon after sevoflurane induction, during emergence, and during post-operative recovery up to a day following anesthesia.  Caution and clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24783, 26887, 'Sevoflurane', 'Seizures', 'The use of sevoflurane has been associated with seizures.  The majority of cases were in children and young adults, most of whom had no medical history of seizures.  Seizures have occurred during, or soon after sevoflurane induction, during emergence, and during post-operative recovery up to a day following anesthesia.  Caution and clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24784, 3647, 'Sibutramine', 'Anorexia Nervosa', 'The use of sibutramine is contraindicated in patients with anorexia nervosa.  Sibutramine is an anorexiant used in the treatment of obesity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24785, 3647, 'Sibutramine', 'Cardiovascular Diseases', 'Sibutramine and its metabolites inhibit the reuptake of norepinephrine, serotonin, and dopamine and can induce substantial increases in heart rate and blood pressure in some patients.  Sibutramine therapy should not be initiated in patients with uncontrolled or poorly controlled hypertension and/or a history of coronary artery disease, arrhythmias, congestive heart failure, stroke, or other severe cardiovascular or cerebrovascular disorders.  All patients treated with sibutramine should have blood pressure and pulse measured prior to starting therapy and monitored at regular intervals thereafter.  Sustained increases in blood pressure or pulse rate may require a dosage reduction or drug discontinuation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24786, 3647, 'Sibutramine', 'Glaucoma', 'Sibutramine and its metabolites inhibit the reuptake of norepinephrine, serotonin, and dopamine and can induce mydriasis.  In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma.  Therapy with sibutramine should be administered cautiously in patients with narrow-angle glaucoma or anatomically narrow angles.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24787, 3647, 'Sibutramine', 'Liver Diseases', 'Sibutramine is converted by the liver to two active metabolites, which are further metabolized to inactive substances and subsequently eliminated by the kidney.  Due to a lack of clinical data, the manufacturer does not recommend the use of sibutramine in patients with severe renal and/or hepatic impairment.  Based on limited pharmacokinetic data, sibutramine may be administered in mild or moderate hepatic insufficiency at normally recommended dosages.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24788, 3647, 'Sibutramine', 'Diabetes Mellitus, Type 2', 'Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight.  Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly.  Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24789, 3647, 'Sibutramine', 'Seizures', 'Sibutramine and its metabolites inhibit the reuptake of norepinephrine, serotonin, and dopamine.  In clinical trials, seizures were reported in < 0.1% of patients treated with sibutramine.  Therapy with sibutramine should be administered cautiously in patients with or predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24790, 3647, 'Sibutramine', 'Substance-Related Disorders', 'Centrally-acting anorexiants are generally subject to habituation and abuse.  While sibutramine does not appear to have a significant potential for abuse, clinical data are limited.  Therapy with sibutramine should be administered cautiously in patients with a history of alcohol or substance abuse.  Such patients should be observed carefully during therapy for signs of misuse of sibutramine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24791, 0, 'Selinexor', 'Gastrointestinal Diseases', 'The use of selinexor can cause gastrointestinal toxicities.  Manage nausea/vomiting/diarrhea by dose interruption, reduction, or discontinuation.  Administer intravenous fluids and replace electrolytes to prevent dehydration in patients at risk.  Use anti-nausea and anti-diarrheal medications as clinically indicated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24792, 0, 'Selinexor', 'Liver Diseases', 'Selinexor is metabolized by CYP450 3A4, multiple UDP-glucuronosyltransferases (UGTs) and glutathione S-transferases (GSTs).  Care is recommended when using this agent in patients with moderate to severe hepatic impairment.  The effect of moderate and severe hepatic impairment on selinexor pharmacokinetics is unknown.  Mild hepatic impairment had no clinically significant effect on the pharmacokinetics of selinexor.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24793, 0, 'Selinexor', 'Hyponatremia', 'The use of selinexor can cause hyponatremia.  Exercise care when using this agent in patients with hyperglycemia and high serum paraprotein levels.  It is recommended to treat hyponatremia per clinical guidelines and to assess hydration and dietary intake.  Interrupt or reduce dose, or permanently discontinue treatment based on severity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24794, 0, 'Selinexor', 'Neurotoxicity Syndromes', 'The use of selinexor may cause neurological toxicities.  Exercise care when using this agent in dehydrated patients and those with anemia.  It is recommended to optimize hydration status and hemoglobin levels to avoid exacerbation of dizziness or mental changes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24795, 0, 'Selinexor', 'Neutropenia', 'The use of selinexor can cause neutropenia.  Exercise care when using this agent in neutropenic patients and those at risk of infections.  Monitor patients for signs and symptoms of concomitant infection, evaluate promptly, and institute measures according to clinical practice.  Interrupt treatment, reduce dose, or permanently discontinue based on severity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24796, 0, 'Selinexor', 'Kidney Diseases', 'No clinically significant differences in the pharmacokinetics of selinexor were observed in patients with mild to severe renal impairment (CrCl 15 to 89 mL/min, estimated by the Cockcroft-Gault equation).  Care is recommended when using this agent in patients with end-stage renal disease (CrCl <15 mL/min) or hemodialysis as the effect on selinexor pharmacokinetics is unknown for these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24797, 0, 'Selinexor', 'Thrombocytopenia', 'The use of selinexor can cause thrombocytopenia.  Exercise care when using this agent in thrombocytopenic patients and those at risk of fatal hemorrhages.  Monitor platelet counts at baseline and periodically as clinically indicated.  Monitor for signs and symptoms of bleeding and interrupt or reduce the dose or permanently discontinue treatment based on severity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24798, 0, 'Selinexor', 'Weight Loss', 'The use of selinexor can cause anorexia and weight loss.  Exercise care in patients with anorexia and those at risk for weight loss.  Manage with dose modifications, appetite stimulants, and nutritional support.  Monitor patient weight at baseline, and regularly during treatment as clinically indicated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24799, 4577, 'Selpercatinib', 'Hemorrhage', 'Serious including fatal hemorrhagic events can occur with the use of selpercatinib.  Care should be exercised when using this agent in patients with bleeding disorders.  It is recommended to permanently discontinue treatment in patients with severe or life-threatening hemorrhage.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24800, 4579, 'Selpercatinib', 'Hemorrhage', 'Serious including fatal hemorrhagic events can occur with the use of selpercatinib.  Care should be exercised when using this agent in patients with bleeding disorders.  It is recommended to permanently discontinue treatment in patients with severe or life-threatening hemorrhage.', '2', '', 'DDInter', 0);
